Search Results - C. Pott

110 | HIGH PFS WITH LOW INFIELD RECURRENCES AFTER LOW DOSE RADIOTHERAPY AND OBINUTUZUMAB IN EARLY STAGE NODAL FOLLICULAR LYMPHOMA: FINAL RESULTS OF THE GAZAI STUDY (GLA 2018‐3) by K. Herfarth, C. W. Scholz, K. Hübel, S. Wirths, C. Buske, J. von Tresckow, R. Forstpointner, S. Heidegger, G. Lenz, J. Meissner, L. König, U. Hoeller, C. Baues, C. de Colle, T. Wiegel, T. Gauler, M. Li, S. E. Combs, H. Eich, P. Thalmann, E. Mavriopoulou, C. Pott, M. Dreyling

Get full text

477 | LONGITUDINAL MULTI‐OMICS INVESTIGATION IN IBRUTINIB‐BORTEZOMIB‐R‐CHOP‐TREATED DLBCL PATIENTS by S. Denker, A. Bittner, M. Frick, J. Kase, J. Hoffmann, C. Trenker, U. Keller, C. Bogner, A. Hüttmann, J. Dürig, M. Janz, S. Mathas, R. Marks, T. Strüßmann, I. Na, P. Richter‐Pechanska, A. Bhattacharya, J. Ihlow, B. Gebauer, L. J. Savic, N. Hübner, C. Pott, M. Khouja, L. Solé‐Boldo, V. Franke, B. Uyar, A. Akalin, L. Bullinger, C. A. Schmitt

Get full text

265 | IMPACT OF IGHV REPERTOIRE AFTER IBRUTINIB‐CONTAINING REGIMENS IN YOUNGER UNTREATED MCL PATIENTS: AN ANALYSIS OF THE TRIANGLE DATA EMBEDDED IN THE MULTIPLY PROJECT by S. Ragaini, R. Moia, K. Gutmair, M. Khouja, E. Genuardi, J. Nabki, P. Nakov, D. Drandi, C. H. Homburg, R. García‐Sanz, P. Gameiro, E. Froňková, B. Schaefer, C. Montana, B. Al Deeban, S. Stilgenbauer, C. U. Niemann, M. Celli, J. Doorduijn, G. Gaidano, E. Giné, M. Gomes da Silva, P. Klener, M. Jerkeman, U. Mey, E. Hoster, A. Evangelista, S. Beà, M. Dreyling, S. Ferrero, C. Pott, M. Ladetto

Get full text

275 | RADIOTHERAPY IN PATIENTS WITH ADVANCED STAGE MANTLE CELL LYMPHOMA ACHIEVES DURABLE LOCAL TUMOR CONTROL—A SAKK/GLA/EMCL REAL‐WORLD‐ANALYSIS FROM THE EMCL‐REGISTRY by L. Simon, S. Drabke, M. Tilch, S. Herold, C. Pott, M. Gomes da Silva, E. Silkenstedt, T. Melchardt, E. Aydilek, C. Renner, V. Vucinic, E. von der Heyde, M. Tometten, A. Kerkhoff, M. Fehr, E. Hofstra, T. W. Kubin, K. Wille, A. Heine, C. Leng, K. Christofyllakis, M. Ahlborn, I. Kohl, J. S. Hecker, L. Hansmann, F. Müller, G. Bisping, M. von Bonin, C. Reinhardt, S. Alig, H. Schmidberger, G. Hess

Get full text

273 | REAL‐WORLD OUTCOMES OF PIRTOBRUTINIB IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: A MULTICENTER ANALYSIS WITH A CONTROL COHORT FROM THE EUROPEAN MCL REGISTRY by E. Aydilek, F. Schwarz, L. Simon, P. Dreger, E. Shumilov, G. Lenz, V. Vucinic, E. Silkenstedt, R. D. Jachimowicz, C. Pott, M. Tometten, C. Leng, M. Ahlborn, F. Müller, M. Maulhardt, G. Wulf, M. Voegeli, K. Sohlbach, K. Schäfer‐Eckart, T. Gaska, R. Greil, I. Kohl, S. Wirths, S. Stilgenbauer, D. Hartnack, M. Topp, S. Dietrich, C. Renner, G. Reiff, P. Marschner, J. Hauser, F. Klaus, M. Bartkowiak, R. Reihs, M. Gomes da Silva, A. Ohler, G. Heß

Get full text

137 | IBRUTINIB ADDED TO MCL TREATMENT HAS STRONG IMPACT ON MRD RESPONSE AND DISEASE KINETICS: RESULTS FROM THE TRIANGLE TRIAL by M. Khouja, V. Jurinovic, S. Ferrero, E. Genuardi, B. Kehden, A. M. Civita, C. U. Niemann, R. García Sanz, A. M. Herrera, C. Homburg, O. J. Verhagen, V. H. van der Velden, S. Kubetzko, E. Fronkova, P. Gameiro, C. Schmidt, J. K. Doorduijn, E. Gine, M. Jerkemann, M. Hutchings, J. Walewski, J. Riise, U. J. Mey, M. Trneny, V. K. Vergote, O. Shpilberg, M. Gomes da Silva, S. Leppä, M. Unterhalt, W. Klapper, E. Hoster, M. Dreyling, M. Ladetto, C. Pott

Get full text

159 | R‐POLA‐GLO – CHEMO‐LIGHT FRONTLINE THERAPY INDUCES HIGH RESPONSE RATES WITH A FAVORABLE SAFETY PROFILE IN ELDERLY/FRAIL PATIENTS WITH AGGRESSIVE LYMPHOMA by R. Wurm‐Kuczera, T. Melchardt, P. Pichler, A. Huster, A. Kerkhoff, M. Panny, R. Schroers, A. Ossami Saidy, F. Müller, F. Damm, M. Orlinger, P. Staber, C. Schwaenen, R. Michael, L. Wohn, C. Schmitt, M. Hoffman, M. Hänel, J. Düll, S. Heyn, S. Mayer, T. Weber, P. Reimer, N. Rotter, U. Schnetzke, B. von Tresckow, G. Kammerer, J. Rasvina, B. Lehner, T. Mika, D. Böckle, C. Leng, A. L. Illert, B. Altmann, B. Friedrichs, E. Willenbacher, D. Mougiakakos, C. Pott, S. Al‐Batran, A. Rosenwald, D. Hellwig, S. Dietrich, B. Glass, G. Lenz, U. Keller, M. Ziepert, R. Greil, B. Chapuy

Get full text